- Processing Solutions
- White Papers
- Tech Portals
- Buyer's Guide
NEW YORK — Pfizer’s pneumonia vaccine has been approved in Europe for use in adults age 50 and older, Bloomberg reported.
Pfizer''s Prevnar 13 vaccine, known as Prevenar 13 outside the U.S., protects against 13 strains of pneumococcal disease, which can cause pneumonia, life-threatening infections of the blood, brain and spinal cord and ear infections in children.
It''s the world''s top-selling vaccine, with about $3.7 billion in annual sales for Prevnar 13 and an earlier, seven-strain version.